Format

Send to

Choose Destination
Swiss Med Wkly. 2014 Aug 7;144:w13990. doi: 10.4414/smw.2014.13990. eCollection 2014.

The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.

Author information

1
Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland; Division of Clinical Immunology and Allergy, University Hospital Lausanne, Switzerland.
2
Division of Internal Medicine and Clinical Immunology Lab, Department of Biomedicine, University Hospital Basel, Switzerland.
3
Division of Clinical Epidemiology, Department of Community Health and Medicine, University Hospital and School of Medicine, Geneva, Switzerland.
4
Division of Nephrology, University Hospital Zurich, Switzerland.
5
Division of Clinical Immunology and Allergy, Sion Hospital, Switzerland.
6
Division of Nephrology, University Hospital Bern, Switzerland.
7
Immunologie-Zentrum, Zurich, Switzerland.
8
Division of Dermatology, University Hospital Bern, Switzerland.
9
Division of Rheumatology, Kantonsspital St Gallen, Switzerland.
10
Division of Clinical Immunology and Allergy, University Hospital Lausanne, Switzerland.
11
Division of Rheumatology, Kantonsspital Schaffhausen, Switzerland.
12
Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland.

Abstract

OBJECTIVES:

To describe disease characteristics and treatment modalities in a multidisciplinary cohort of systemic lupus erythematosus (SLE) patients in Switzerland.

METHODS:

Cross-sectional analysis of 255 patients included in the Swiss SLE Cohort and coming from centres specialised in Clinical Immunology, Internal Medicine, Nephrology and Rheumatology. Clinical data were collected with a standardised form. Disease activity was assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), an integer physician's global assessment score (PGA) ranging from 0 (inactive) to 3 (very active disease) and the erythrocyte sedimentation rate (ESR). The relationship between SLE treatment and activity was assessed by propensity score methods using a mixed-effect logistic regression with a random effect on the contributing centre.

RESULTS:

Of the 255 patients, 82% were women and 82% were of European ancestry. The mean age at enrolment was 44.8 years and the median SLE duration was 5.2 years. Patients from Rheumatology had a significantly later disease onset. Renal disease was reported in 44% of patients. PGA showed active disease in 49% of patients, median SLEDAI was 4 and median ESR was 14 millimetre/first hour. Prescription rates of anti-malarial drugs ranged from 3% by nephrologists to 76% by rheumatologists. Patients regularly using anti-malarial drugs had significantly lower SELENA-SLEDAI scores and ESR values.

CONCLUSION:

In our cohort, patients in Rheumatology had a significantly later SLE onset than those in Nephrology. Anti-malarial drugs were mostly prescribed by rheumatologists and internists and less frequently by nephrologists, and appeared to be associated with less active SLE.

PMID:
25115978
DOI:
10.4414/smw.2014.13990
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for EMH Swiss Medical Publishers Ltd.
Loading ...
Support Center